[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100054209":3},{"organization":4,"outcomesModule":7,"designInfo":31,"detailedDescription":11,"studyPopulation":11,"armGroups":37,"interventions":44,"overallOfficials":51,"centralContacts":55,"locations":64,"responsibleParty":185,"collaborators":11,"id":187,"slug":188,"hasResults":189,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":189,"sex":195,"minAge":196,"maxAge":11,"enrollmentInfo":197,"targetDuration":11,"studyType":200,"phases":201,"briefSummary":203,"conditions":204,"keywords":206,"overallStatus":67,"whyStopped":11,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":226},{"fullName":5,"class":6},"Exelixis","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Objective Response Rate (ORR) per Response Assessment in Neuro-oncology (RANO) as Assessed by Blinded Independent Central Review (BICR)",null,"Up to approximately 12 months",[14,17,20,22,24,26,29],{"measure":15,"description":11,"timeFrame":16},"Progression-free Survival at 6 Months (PFS-6) per RANO as Assessed by BICR and Investigator","Up to 6 months",{"measure":18,"description":11,"timeFrame":19},"Duration of Response (DOR) per RANO as Assessed by BICR and Investigator","Up to approximately 48 months",{"measure":21,"description":11,"timeFrame":19},"Progression-free Survival (PFS) per RANO as Assessed by BICR and Investigator",{"measure":23,"description":11,"timeFrame":19},"Overall Survival (OS)",{"measure":25,"description":11,"timeFrame":19},"Number of Participants with Treatment-emergent Adverse Events (TEAEs)",{"measure":27,"description":11,"timeFrame":28},"Change from Baseline in Neurologic Function as Measured by the Neurologic Assessment in Neuro-oncology (NANO) Scale Score","Baseline up to approximately 13 months",{"measure":30,"description":11,"timeFrame":28},"Change from Baseline in Health-related Quality of Life (HRQoL) as Measured by the EuroQol 5-dimension 5-level Questionnaire (EQ-5D-5L) Score",{"allocation":32,"interventionModel":33,"interventionModelDescription":11,"primaryPurpose":34,"observationalModel":11,"timePerspective":11,"maskingInfo":35},"NA","SINGLE_GROUP","TREATMENT",{"masking":36,"maskingDescription":11,"whoMasked":11},"NONE",[38],{"label":39,"type":40,"description":41,"interventionNames":42},"Zanzalintinib","EXPERIMENTAL","Participants will receive zanzalintinib once daily (QD).",[43],"Drug: Zanzalintinib",[45],{"type":46,"name":39,"description":47,"armGroupLabels":48,"otherNames":49},"DRUG","Administered as specified in the treatment arm.",[39],[50],"XL092",[52],{"name":53,"affiliation":5,"role":54},"Study Director","STUDY_DIRECTOR",[56,61],{"name":57,"role":58,"phone":59,"phoneExt":11,"email":60},"Exelixis Clinical Trials","CONTACT","1-888-EXELIXIS (888-393-5494)","druginfo@exelixis.com",{"name":62,"role":58,"phone":63,"phoneExt":11,"email":11},"Backup or International","650-837-7400",[65,79,89,99,108,118,127,136,146,156,165,175],{"facility":66,"status":67,"city":68,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":11},"University of Alabama","RECRUITING","Birmingham","Alabama","35294","United States","US",{"type":74,"coordinates":75},"Point",[76,77],-86.80249,33.52066,{"lat":77,"lon":76},{"facility":80,"status":67,"city":81,"state":82,"zip":83,"country":71,"countryCode":72,"cosmosGeoPoint":84,"geoPoint":88,"contacts":11},"Mayo Clinic_Arizona","Phoenix","Arizona","85054",{"type":74,"coordinates":85},[86,87],-112.07404,33.44838,{"lat":87,"lon":86},{"facility":90,"status":67,"city":91,"state":92,"zip":93,"country":71,"countryCode":72,"cosmosGeoPoint":94,"geoPoint":98,"contacts":11},"Mayo Clinic_Jacksonville","Jacksonville","Florida","32224",{"type":74,"coordinates":95},[96,97],-81.65565,30.33218,{"lat":97,"lon":96},{"facility":100,"status":67,"city":101,"state":92,"zip":102,"country":71,"countryCode":72,"cosmosGeoPoint":103,"geoPoint":107,"contacts":11},"Baptist Health Miami Cancer Institute","Miami","33176",{"type":74,"coordinates":104},[105,106],-80.19366,25.77427,{"lat":106,"lon":105},{"facility":109,"status":67,"city":110,"state":111,"zip":112,"country":71,"countryCode":72,"cosmosGeoPoint":113,"geoPoint":117,"contacts":11},"Washington University School of Medicine","Bay Saint Louis","Mississippi","63110",{"type":74,"coordinates":114},[115,116],-89.33005,30.30881,{"lat":116,"lon":115},{"facility":119,"status":67,"city":120,"state":120,"zip":121,"country":71,"countryCode":72,"cosmosGeoPoint":122,"geoPoint":126,"contacts":11},"Memorial Sloan-Kettering Cancer Center","New York","10065",{"type":74,"coordinates":123},[124,125],-74.00597,40.71427,{"lat":125,"lon":124},{"facility":128,"status":67,"city":129,"state":120,"zip":130,"country":71,"countryCode":72,"cosmosGeoPoint":131,"geoPoint":135,"contacts":11},"Mayo Clinic_Rochester","Rochester","55905",{"type":74,"coordinates":132},[133,134],-77.61556,43.15478,{"lat":134,"lon":133},{"facility":137,"status":67,"city":138,"state":139,"zip":140,"country":71,"countryCode":72,"cosmosGeoPoint":141,"geoPoint":145,"contacts":11},"Duke University","Durham","North Carolina","27710",{"type":74,"coordinates":142},[143,144],-78.89862,35.99403,{"lat":144,"lon":143},{"facility":147,"status":67,"city":148,"state":149,"zip":150,"country":71,"countryCode":72,"cosmosGeoPoint":151,"geoPoint":155,"contacts":11},"UT MD Anderson Cancer Center","Houston","Texas","77030",{"type":74,"coordinates":152},[153,154],-95.36327,29.76328,{"lat":154,"lon":153},{"facility":157,"status":67,"city":158,"state":149,"zip":159,"country":71,"countryCode":72,"cosmosGeoPoint":160,"geoPoint":164,"contacts":11},"UT Health San Antonio Mays Cancer Center","San Antonio","78229",{"type":74,"coordinates":161},[162,163],-98.49363,29.42412,{"lat":163,"lon":162},{"facility":166,"status":67,"city":167,"state":168,"zip":169,"country":71,"countryCode":72,"cosmosGeoPoint":170,"geoPoint":174,"contacts":11},"Inova Center for Personalized Health","Fairfax","Virginia","22031",{"type":74,"coordinates":171},[172,173],-77.30637,38.84622,{"lat":173,"lon":172},{"facility":176,"status":67,"city":177,"state":178,"zip":179,"country":71,"countryCode":72,"cosmosGeoPoint":180,"geoPoint":184,"contacts":11},"UW Carbone Cancer Center","Madison","Wisconsin","53792",{"type":74,"coordinates":181},[182,183],-89.40123,43.07305,{"lat":183,"lon":182},{"type":186,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100054209","phase-2-a-study-of-zanzalintinib-in-participants-with-recurrent-or-progressive-meningioma-100054209",false,"NCT07428616","A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma","A Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma","STELLAR-201","Key Inclusion Criteria:\n\n* Histologically confirmed World Health Organization (WHO) grade 1, 2, or 3 meningioma.\n* Developed recurrent disease or progressive disease (PD) after receiving standard therapy (for example, surgery and\u002For radiation) or have been deemed ineligible to receive these therapies. At least 1 prior course of meningioma-directed radiotherapy is required, if not contraindicated.\n* Radiologically documented progression of any existing tumor (growth \\> 15% of the bidimensional enhancing tumor within the prior 6 months or appearance of new lesions (including intra and extracranial manifestations).\n* For participants treated with external beam radiation, interstitial brachytherapy, or radiosurgery, an interval ≥ 24 weeks must have elapsed from completion of therapy to initiation of treatment.\n* Measurable disease by RANO meningioma criteria as determined by the investigator, obtained ≤ 14 days prior to initiation of treatment.\n* Karnofsky performance status (KPS) ≥ 60%.\n* Demonstrate adequate organ and marrow function within 14 days of treatment initiation\n\nKey Exclusion Criteria:\n\n* Prior history of hypertensive encephalopathy at any time.\n* Extracranial lesions invading major blood vessels including, but not limited to, inferior vena cava, pulmonary artery, or aorta.\n* Contraindication to magnetic resonance imaging (MRI).\n* Local therapy (surgery and\u002For radiation therapy) is indicated per investigator\n* Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks or 5 half-lives, whichever is shorter, before initiation of treatment. There is no limit on prior systemic therapies\n* Prior Surgery - completed wound healing must occur prior to initiation of treatment; ≥ 8 weeks for major surgery, ≥ 7 days for minor surgery, including stereotactic biopsies.\n* The participant has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n  * Cardiovascular disorders, including uncontrolled hypertension,\n  * Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation,\n  * Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 milliliters \\[mL\\]) of red blood within 12 weeks before initiation of treatment or other history of significant bleeding (eg, intracranial hemorrhage\u002Fbleeding), or\n  * Other clinically significant disorders.\n* Requirement for hemodialysis or peritoneal dialysis.\n* History of solid organ or allogeneic stem cell transplant.\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years",{"count":198,"type":199},100,"ESTIMATED","INTERVENTIONAL",[202],"PHASE2","The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.",[205],"Meningioma",[205,207,208,209,210,211,39,50,212,213,214,215,216],"Recurrent Meningioma","Progressive Meningioma","Atypical Meningioma","Anaplastic Meningioma","Brain","Grade 1 Meningioma","Grade 2 Meningioma","Grade 3 Meningioma","Intracranial Neoplasms","Extracranial Meningioma","2026-07-10",{"date":219,"type":220},"2026-07-13","ACTUAL",{"date":222,"type":220},"2026-05-21",{"date":224,"type":199},"2029-09-30",{"name":5,"class":6},12]